1. 1) Akita H, Fujiwara T, Santiwarangkool S, Hossen N, Kajimoto K, El-Sayed A, Tabata Y, Harashima H. Transcytosis-targeting peptide: a conductor of liposomal nanoparticles through the endothelial cell barrier. Small, 12, 1212–1221 (2016).
2. 2) Gabizon A, Goren D, Horowitz AT, Tzemach D, Lossos A, Siegal T. Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals. Adv. Drug Deliv. Rev., 24, 337–344 (1997).
3. 3) Fukuta T, Ishii T, Asai T, Oku N. Applications of liposomal drug delivery systems to develop neuroprotective agents for the treatment of ischemic stroke. Biol. Pharm. Bull., 42, 319–326 (2019).
4. 4) Metselaar JM, Storm G. Liposomes in the treatment of inflammatory disorders. Expert Opin. Drug Deliv., 2, 465–476 (2005).
5. 5) Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv. Drug Deliv. Rev., 65, 71–79 (2013).